Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
National Heart, Lung, and Blood Institute, (2001),
[2.]
National Heart, Lung, and Blood Institute, (1993),
[3.]
S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[4.]
Y. Cui, R.S. Blumenthal, A. Flaws, M.K. Whiteman, P. Langenberg, P.S. Bachorik, et al.
Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.
Arch Intern Med, 161 (2001), pp. 1413-1419
[5.]
G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, D. Watters, et al.
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
JAMA, 285 (2001), pp. 1711-1718
[6.]
M.A. Austin, J.E. Hokanson, K.L. Edwards.
Hypertriglyceridemia as a cardiovascular risk factor.
Am J Cardiol, 81 (1998), pp. 7-12
[7.]
G. Assman, H. Schulte, H. Funke, A. von Eckardstein.
The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
Eur Heart J, 19 (1998), pp. 8-14
[8.]
S. Miremadi, A. Sniderman, J. Frohlich.
Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?.
Clin Chem, 48 (2002), pp. 484-488
[9.]
A.M. Wagner, A. Pérez, F. Calvo, R. Bonet, A. Castellvi, J. Ordóñez.
Apolipoprotein (B) identifies dyslipemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients.
Diabetes Care, 22 (1999), pp. 812-817
[10.]
C.D. Gardner, S.P. Fortmann, R.M. Krauss.
Association of small lowdensity lipoprotein particles with the incidence of coronary artery disease in men and women.
JAMA, 276 (1996), pp. 875-881
[11.]
B.D. Miller, E.L. Alderman, W.L. Haskell, J.M. Fair, R.M. Krauss.
Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.
Circulation, 94 (1996), pp. 2146-2153
[12.]
P.S. Bachorik, J.W. Ross.
for the National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary.
Clin Chem, 41 (1995), pp. 1414-1420
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.